PrimaryMarkets

VIEW OUR WEBINARS

SOFI Spritz - Australia’s Aperitivo
SOFI Spritz - Australia’s Aperitivo
View Recording

Deal Snapshot - 21 September 2018
Deal Snapshot - 21 September 2018
View Recording

Pre-IPO Trading with PrimaryMarkets
Pre-IPO Trading with PrimaryMarkets
View Recording

AIRR - Profile Video
AIRR - Profile Video
View Recording

Deal Snapshot - 31 August 2018
Deal Snapshot - 31 August 2018
View Recording

Cancer Diagnostics Company - Pre-IPO Existing Shareholding - FDA Listed ISO13485 Certified

Categories: Securities, Pre-IPO / Grey Market
Sale Type: Asking Price
Price Guide: AUD 6M shares @ $0.14 per share (cum rights) = 24.32% discount to December 2016 Pre-IPO Rights Issue
Status: Closed

Summary:

Sale of pre-IPO existing shares by a motivated Seller in a public, unlisted Company based in Melbourne, Australia. Since 2007, the Company has successfully realised IP value in telomerase-based diagnostics to effectively identify bladder cancer. In 2016 it transitioned from a purely R&D company to a commercial entity with product revenues. Has recently formalised distribution agreements for US and UK markets. Since inception, the Company has raised A$16.1M in equity to successfully achieve milestones and has been well supported by considerable R&D Incentives. 

Share this Listing

 

Go Back

Become a Follower